; and (4) recommendations for enhancing patient awareness of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, including early identification of risk factors and linkage to appropriate care. (c) Report The agreement entered into under subsection (a) shall require the National Academies of Sciences to, not later than January 1, 2022, submit a report on the findings of the study to the Secretary and the Chairman and Ranking Member of each of the following committees: (1) The Committee on Energy and Commerce of the House of Representatives. (2) The Committee on Ways and Means of the House of Representatives. (3) The Committee on Finance of the Senate. (4) The Committee on Health, Education, Labor, and Pensions of the Senate. (d) Authorization of appropriations There are authorized to be appropriated to carry out this section $1,000,000 for each of fiscal years 2021 and 2022. 5. National surveillance program for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (a) In general The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, shall establish a program to provide for surveillance on the prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States. (b) Program activities (1) Surveillance activities The program established under subsection (a) shall include, at a minimum, each of the following surveillance activities: (A) Conducting local surveillance activities to collect data on the prevalence and severity of nonalcoholic fatty level disease and nonalcoholic steatohepatitis. (B) Compiling and annually publishing data on the number of individuals with nonalcoholic fatty level disease and nonalcoholic steatohepatitis nationally as well as in each state. (C) To the extent practicable, providing data on the general population at risk of developing the conditions. (2) Technical assistance on vital statistics In carrying out the program under subsection (a), the Secretary of Health